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T
he promise of a cancer 
vaccination to ﬁ  ght tumors 
using the patient’s own immune 
system is at the same time fascinating 
and challenging. Since cancer typically 
strikes at an older age, there is no 
evolutionary pressure on the immune 
system to develop successful anticancer 
effectors. This lack of evolutionary 
pressure to ﬁ  ght cancer is an apparent 
contrast to infectious diseases, for which 
a reasonable argument can be made 
that the immune system has evolved 
to ﬁ  ght pathogens. These assumptions 
might explain the relative success of 
vaccine development in the area of 
infectious diseases, and the long history 
of failed attempts in cancer vaccination. 
And yet there is overwhelming 
evidence from laboratory studies that 
speciﬁ  c effectors of the immune system 
are able to recognize and destroy 
cancer cells. Soluble effectors of the 
immune system, such as antibodies, 
are now reliable weapons in the ﬁ  ght 
against lymphomas [1]. The graft-
versus-leukemia effect (immunological 
rejection of leukemia cells following 
bone marrow transplantation) strongly 
indicates the power of the immune 
system to control certain tumors [2]. 
Thus, the immune system, even though 
primarily evolved to ﬁ  ght pathogens, 
clearly has the means to ﬁ  ght cancer.
Challenges of Cancer Vaccination 
What are the prerequisites for 
a successful anticancer immune 
response? Before destruction of a 
tumor is achieved by the host immune 
system, a simpliﬁ  ed four-step scenario 
has to take place: (1) activation and 
expansion of tumor-speciﬁ  c effector 
cells, (2) migration of effector cells 
to the tumor site, (3) effector-cell 
recognition of tumor cells, and (4) 
effector-cell destruction of tumor cells. 
In addition, a quantitative balance 
between the number of tumor cells 
and effector cells needed to destroy the 
tumor has to be taken into account. 
All these steps need to be investigated 
and controlled for successful cancer 
vaccination. 
Cytotoxic T cells are among the 
best-investigated effector cells of 
the immune system. There is strong 
evidence that the presence of 
intratumoral T cells correlates with 
improved clinical outcome in certain 
human cancers during the natural 
immune response against tumors [3]. 
Dendritic cells are among the most 
powerful activators of tumor-speciﬁ  c 
helper cells and cytotoxic T cells [4]. 
Expansion of human tumor antigen-
speciﬁ  c helper cells and cytotoxic T 
cells in peripheral blood has been 
demonstrated using antigen-pulsed 
dendritic cells as well as intracutaneous 
peptide immunization in the presence 
or absence of adjuvant [5–7]. 
There is, however, limited insight 
into the magnitude, breadth, and 
molecular nature of the induced 
immune responses. There are also 
currently no means to discriminate 
between protective and nonprotective 
(curative and noncurative) T cell 
responses. In fact, we are not certain 
about the frequency of tumor antigen-
speciﬁ  c T cells that is necessary 
for tumor destruction. While viral 
protection models suggest that a 
high frequency (number) of vaccine-
induced speciﬁ  c effectors is necessary, 
alternative hypotheses favor the 
generation of low-frequency vaccine-
induced responses, which might in turn 
affect pre-existing antitumor-speciﬁ  c T 
cells [8]. Therefore, new developments 
in the area of monitoring and 
understanding the tumor-speciﬁ  c 
immune response, in combination with 
small innovative pilot vaccine trials, are 
needed.
Monitoring of the Cancer Immune 
Response
There are many ways to assess a cancer-
speciﬁ  c immune response, including 
monitoring (1) direct cytotoxicity of 
effectors, as measured by chromium 
release assays (see Glossary), (2) 
cytokine release from effector cells, 
as assessed by ﬂ  ow cytometry or 
enzyme-linked immunosorbent 
assay techniques, (3) T cell receptor 
(TCR) speciﬁ  cities, as assessed by 
MHC-peptide multimers, (4) clonal 
composition of the T cell response via 
CDR (complementarity-determining 
region) 3 spectratyping, and (5) T cell 
degranulation via cell surface exposure 
of cluster designation (CD)107 [9–11]. 
Many of these techniques are 
useful, but fail to fully assess the 
functional complexity of an anticancer 
T cell response in a comprehensive 
manner. Analyzing T cell speciﬁ  cities 
using MHC-peptide multimers has 
revolutionized the ﬁ  eld of cancer 
vaccination, but does not provide 
insights into T cell function. Detection 
of interferon-γ production by tumor-
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speciﬁ  c T cells gives some functional 
insights, but lacks information about 
TCR speciﬁ  cities and does not cover 
the broad spectrum of potential 
effector cytokines. Indeed, studies of 
chronic viral infection models suggest 
the relevance of multiple cytokines 
such as interferon γ, interleukin 2, and 
tumor necrosis factor α for effector T 
cell ﬁ  tness [12]. 
A New Study of a Novel 
Immunomonitoring Tool
A new study by Chen et al. in the current 
issue of PLoS Medicine provides a novel 
approach to these scientiﬁ  c issues, and 
increases our insight into the vaccine-
induced anticancer immune response 
using a novel immunomonitoring tool 
[13]. The tool combines analysis of TCR 
speciﬁ  cities with detection of cytokine 
production in a multiparametric 
microarray platform. The authors 
array HLA-A2-immunoglobulin dimers 
loaded with the peptide of interest 
with cytokine-capturing antibodies on 
three-dimensional substrates composed 
of microscope slides coated with a 
polyacrylamide gel. This allows the 
comprehensive analysis of multiple 
T cell speciﬁ  cities and functional 
outcomes. Similar platforms were 
recently used to investigate antigen-
speciﬁ  c T cell clones [14]. The current 
study, however, provides the ﬁ  rst 
comprehensive analysis of vaccine-
induced antitumor immune responses 
in patients with cancer.
One of the most striking ﬁ  ndings 
is the marked variation of responses 
toward well-deﬁ  ned peptide vaccines. 
Variation of the response was seen 
both at the level of a single patient 
and, independently, at the level of the 
speciﬁ  c antigen. Thus, no patient or 
antigen-speciﬁ  c functional response 
pattern was observed. Even though the 
current study does not allow deﬁ  nitive 
conclusions about a link between 
speciﬁ  c cytokine secretion proﬁ  les and 
clinical outcomes, it appears as if both 
interferon γ and tumor necrosis factor 
α were relevant for tumor clearance, as 
indicated by prolonged recurrence-free 
periods in patients with such a cytokine 
proﬁ  le. 
Implications of the Study
The study raises several questions. 
Are cytokine signatures present in 
certain subpopulations of effector 
T cells, especially those successful 
in tumor rejection? Are cytokine 
signatures predictive of the clinical 
outcome? It will be interesting to test 
T cell subpopulations, especially those 
derived from secondary lymphoid 
tissues and the tumor site. Are there 
cytokine signatures in response to 
pathogens or pathogen-speciﬁ  c 
vaccines, and how do these signatures 
differ from those induced by cancer 
vaccines? Antibody responses might 
be detected by protein microarrays 
[15]. Are there ways to array and 
functionally analyze other components 
of the immune system such as NKT 
cells, NK cells, or granulocytes? 
Taken together, the current study 
establishes the fundamentals for 
future application of high-throughput 
multiparametric platforms that 
simultaneously capture antigen-speciﬁ  c 
T cells and detect secreted products in 
the analysis of tumor and, potentially, 
pathogen-speciﬁ  c immune responses.  
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Glossary
Cluster designation (CD) 107: A lysomal 
membrane protein that translocates to 
the cell surface during the killing process.
CDR3 spectratyping: CDRs of TCRs 
are the parts of these molecules 
that determine their speciﬁ  city and 
make contact with speciﬁ  c ligands. 
Spectratyping deﬁ  nes certain types of 
DNA gene segments that constitute the 
CDR.
Chromium release assay: Assay for 
cytotoxic activity of killer cells.
Enzyme-linked immunosorbent assay 
(ELISA): A serological assay in which a 
bound antigen or antibody is detected by 
a linked enzyme that converts a colorless 
substrate into a colored product.
Flow cytometry: Analysis of biological 
material by detection of light-absorbing 
or ﬂ  uorescing properties of cells.
HLA-A2-Immunoglobulin dimers:
Dimers of human leukocyte antigen 
domains fused to an immunoglobulin 
scaffold. 
MHC-peptide multimers: MHC-peptide 
multimers detect vaccine-speciﬁ  c T cells.
Multiparametric microarray platform:
Platform to assess multiple parameters at 
once on a small glass chip.
NK cells: NK cells are large, granular non-
T, non-B lymphocytes that kill certain 
tumor cells.
NKT cells: NKT cells are lymphocytes that 
share features of both T cells and NK cells.
TCR speciﬁ  cities: Speciﬁ  c TCRs 
recognizing MHC-peptide complexes.
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